Adjuvant treatment of Parkinson's disease with budipine: a double-blind trial versus placebo
Identifieur interne : 000A45 ( Main/Corpus ); précédent : 000A44; suivant : 000A46Adjuvant treatment of Parkinson's disease with budipine: a double-blind trial versus placebo
Auteurs : Kurt Jellinger ; Harald BliesathSource :
- Journal of Neurology [ 0340-5354 ] ; 1987-06-01.
Abstract
Summary: Budipine, a new 4,4-diphenylpiperidine derivative, and placebo were administered three times daily to 31 patients with Parkinson's disease over a period of 12 weeks. All patients in the two treatment groups received levodopa (plus benserazide) at an optimum and constant dose for at least 2 months before the start of the study and throughout the trial. The additional administration of budipine (daily dose 60 mg) was excellently tolerated by 14 patients, while 2 patients left the study because of mental confusion at an early stage of the trial. The budipine group showed a 22% improvement on the Columbia Rating Scale (median score). Compared with the placebo group (4% improvement), there was a highly significant difference (P<0.01, one-tailed test). Of the three main symptoms of Parkinson's disease, the best effect was seen on tremor, and less pronounced effects on bradykinesia and rigidity. Owing to its long half-life (31 h) with little plasma level fluctuations, budipine appears to be an effective agent in the treatment of Parkinson's disease.
Url:
DOI: 10.1007/BF00314280
Links to Exploration step
ISTEX:736AE8781BD70ADB7075C0C3EF16996111DBDE1BLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Adjuvant treatment of Parkinson's disease with budipine: a double-blind trial versus placebo</title><author><name sortKey="Jellinger, Kurt" sort="Jellinger, Kurt" uniqKey="Jellinger K" first="Kurt" last="Jellinger">Kurt Jellinger</name><affiliation><mods:affiliation>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology, Lainz Hospital, Wolkersbergenstrasse 1, A-1130, Vienna, Austria</mods:affiliation></affiliation></author><author><name sortKey="Bliesath, Harald" sort="Bliesath, Harald" uniqKey="Bliesath H" first="Harald" last="Bliesath">Harald Bliesath</name><affiliation><mods:affiliation>Byk Gulden Research Center, D-7750, Konstanz, Federal Republic of Germany</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:736AE8781BD70ADB7075C0C3EF16996111DBDE1B</idno><date when="1987" year="1987">1987</date><idno type="doi">10.1007/BF00314280</idno><idno type="url">https://api.istex.fr/document/736AE8781BD70ADB7075C0C3EF16996111DBDE1B/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000A45</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Adjuvant treatment of Parkinson's disease with budipine: a double-blind trial versus placebo</title><author><name sortKey="Jellinger, Kurt" sort="Jellinger, Kurt" uniqKey="Jellinger K" first="Kurt" last="Jellinger">Kurt Jellinger</name><affiliation><mods:affiliation>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology, Lainz Hospital, Wolkersbergenstrasse 1, A-1130, Vienna, Austria</mods:affiliation></affiliation></author><author><name sortKey="Bliesath, Harald" sort="Bliesath, Harald" uniqKey="Bliesath H" first="Harald" last="Bliesath">Harald Bliesath</name><affiliation><mods:affiliation>Byk Gulden Research Center, D-7750, Konstanz, Federal Republic of Germany</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neurology</title><title level="j" type="abbrev">J Neurol</title><idno type="ISSN">0340-5354</idno><idno type="eISSN">1432-1459</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><date type="published" when="1987-06-01">1987-06-01</date><biblScope unit="volume">234</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="280">280</biblScope><biblScope unit="page" to="282">282</biblScope></imprint><idno type="ISSN">0340-5354</idno></series><idno type="istex">736AE8781BD70ADB7075C0C3EF16996111DBDE1B</idno><idno type="DOI">10.1007/BF00314280</idno><idno type="ArticleID">Art2</idno><idno type="ArticleID">BF00314280</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0340-5354</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Summary: Budipine, a new 4,4-diphenylpiperidine derivative, and placebo were administered three times daily to 31 patients with Parkinson's disease over a period of 12 weeks. All patients in the two treatment groups received levodopa (plus benserazide) at an optimum and constant dose for at least 2 months before the start of the study and throughout the trial. The additional administration of budipine (daily dose 60 mg) was excellently tolerated by 14 patients, while 2 patients left the study because of mental confusion at an early stage of the trial. The budipine group showed a 22% improvement on the Columbia Rating Scale (median score). Compared with the placebo group (4% improvement), there was a highly significant difference (P<0.01, one-tailed test). Of the three main symptoms of Parkinson's disease, the best effect was seen on tremor, and less pronounced effects on bradykinesia and rigidity. Owing to its long half-life (31 h) with little plasma level fluctuations, budipine appears to be an effective agent in the treatment of Parkinson's disease.</div></front></TEI><istex><corpusName>springer</corpusName><author><json:item><name>Kurt Jellinger</name><affiliations><json:string>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology, Lainz Hospital, Wolkersbergenstrasse 1, A-1130, Vienna, Austria</json:string></affiliations></json:item><json:item><name>Harald Bliesath</name><affiliations><json:string>Byk Gulden Research Center, D-7750, Konstanz, Federal Republic of Germany</json:string></affiliations></json:item></author><articleId><json:string>Art2</json:string><json:string>BF00314280</json:string></articleId><language><json:string>eng</json:string></language><abstract>Summary: Budipine, a new 4,4-diphenylpiperidine derivative, and placebo were administered three times daily to 31 patients with Parkinson's disease over a period of 12 weeks. All patients in the two treatment groups received levodopa (plus benserazide) at an optimum and constant dose for at least 2 months before the start of the study and throughout the trial. The additional administration of budipine (daily dose 60 mg) was excellently tolerated by 14 patients, while 2 patients left the study because of mental confusion at an early stage of the trial. The budipine group showed a 22% improvement on the Columbia Rating Scale (median score). Compared with the placebo group (4% improvement), there was a highly significant difference (P>0.01, one-tailed test). Of the three main symptoms of Parkinson's disease, the best effect was seen on tremor, and less pronounced effects on bradykinesia and rigidity. Owing to its long half-life (31 h) with little plasma level fluctuations, budipine appears to be an effective agent in the treatment of Parkinson's disease.</abstract><qualityIndicators><score>4.125</score><pdfVersion>1.3</pdfVersion><pdfPageSize>598 x 792 pts</pdfPageSize><refBibsNative>false</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>1067</abstractCharCount><pdfWordCount>2121</pdfWordCount><pdfCharCount>13024</pdfCharCount><pdfPageCount>3</pdfPageCount><abstractWordCount>167</abstractWordCount></qualityIndicators><title>Adjuvant treatment of Parkinson's disease with budipine: a double-blind trial versus placebo</title><genre><json:string>research-article</json:string></genre><host><volume>234</volume><pages><last>282</last><first>280</first></pages><issn><json:string>0340-5354</json:string></issn><issue>5</issue><subject><json:item><value>Neurosciences</value></json:item><json:item><value>Neuroradiology</value></json:item><json:item><value>Neurology</value></json:item></subject><journalId><json:string>415</json:string></journalId><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1432-1459</json:string></eissn><title>Journal of Neurology</title><publicationDate>1987</publicationDate><copyrightDate>1987</copyrightDate></host><publicationDate>1987</publicationDate><copyrightDate>1987</copyrightDate><doi><json:string>10.1007/BF00314280</json:string></doi><id>736AE8781BD70ADB7075C0C3EF16996111DBDE1B</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/736AE8781BD70ADB7075C0C3EF16996111DBDE1B/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/736AE8781BD70ADB7075C0C3EF16996111DBDE1B/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/736AE8781BD70ADB7075C0C3EF16996111DBDE1B/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Adjuvant treatment of Parkinson's disease with budipine: a double-blind trial versus placebo</title><respStmt xml:id="ISTEX-API" resp="Références bibliographiques récupérées via GROBID" name="ISTEX-API (INIST-CNRS)"></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><availability><p>SPRINGER</p></availability><date>1986-07-14</date></publicationStmt><notesStmt><note>Original Investigations</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Adjuvant treatment of Parkinson's disease with budipine: a double-blind trial versus placebo</title><author corresp="yes"><persName><forename type="first">Kurt</forename><surname>Jellinger</surname></persName><affiliation>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology, Lainz Hospital, Wolkersbergenstrasse 1, A-1130, Vienna, Austria</affiliation></author><author><persName><forename type="first">Harald</forename><surname>Bliesath</surname></persName><affiliation>Byk Gulden Research Center, D-7750, Konstanz, Federal Republic of Germany</affiliation></author></analytic><monogr><title level="j">Journal of Neurology</title><title level="j" type="abbrev">J Neurol</title><idno type="JournalID">415</idno><idno type="pISSN">0340-5354</idno><idno type="eISSN">1432-1459</idno><idno type="IssueArticleCount">21</idno><idno type="VolumeIssueCount">6</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><date type="published" when="1987-06-01"></date><biblScope unit="volume">234</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="280">280</biblScope><biblScope unit="page" to="282">282</biblScope></imprint></monogr><idno type="istex">736AE8781BD70ADB7075C0C3EF16996111DBDE1B</idno><idno type="DOI">10.1007/BF00314280</idno><idno type="ArticleID">Art2</idno><idno type="ArticleID">BF00314280</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1986-07-14</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Summary: Budipine, a new 4,4-diphenylpiperidine derivative, and placebo were administered three times daily to 31 patients with Parkinson's disease over a period of 12 weeks. All patients in the two treatment groups received levodopa (plus benserazide) at an optimum and constant dose for at least 2 months before the start of the study and throughout the trial. The additional administration of budipine (daily dose 60 mg) was excellently tolerated by 14 patients, while 2 patients left the study because of mental confusion at an early stage of the trial. The budipine group showed a 22% improvement on the Columbia Rating Scale (median score). Compared with the placebo group (4% improvement), there was a highly significant difference (P<0.01, one-tailed test). Of the three main symptoms of Parkinson's disease, the best effect was seen on tremor, and less pronounced effects on bradykinesia and rigidity. Owing to its long half-life (31 h) with little plasma level fluctuations, budipine appears to be an effective agent in the treatment of Parkinson's disease.</p></abstract><textClass><keywords scheme="Journal Subject"><list><head>Medicine & Public Health</head><item><term>Neurosciences</term></item><item><term>Neuroradiology</term></item><item><term>Neurology</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1986-07-14">Created</change><change when="1987-06-01">Published</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2016-3-2">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/736AE8781BD70ADB7075C0C3EF16996111DBDE1B/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Springer, Publisher found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//Springer-Verlag//DTD A++ V2.4//EN" URI="http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd" name="istex:docType"></istex:docType><istex:document><Publisher><PublisherInfo><PublisherName>Springer-Verlag</PublisherName><PublisherLocation>Berlin/Heidelberg</PublisherLocation></PublisherInfo><Journal><JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered"><JournalID>415</JournalID><JournalPrintISSN>0340-5354</JournalPrintISSN><JournalElectronicISSN>1432-1459</JournalElectronicISSN><JournalTitle>Journal of Neurology</JournalTitle><JournalAbbreviatedTitle>J Neurol</JournalAbbreviatedTitle><JournalSubjectGroup><JournalSubject Type="Primary">Medicine & Public Health</JournalSubject><JournalSubject Type="Secondary">Neurosciences</JournalSubject><JournalSubject Type="Secondary">Neuroradiology</JournalSubject><JournalSubject Type="Secondary">Neurology</JournalSubject></JournalSubjectGroup></JournalInfo><Volume><VolumeInfo VolumeType="Regular" TocLevels="0"><VolumeIDStart>234</VolumeIDStart><VolumeIDEnd>234</VolumeIDEnd><VolumeIssueCount>6</VolumeIssueCount></VolumeInfo><Issue IssueType="Regular"><IssueInfo TocLevels="0"><IssueIDStart>5</IssueIDStart><IssueIDEnd>5</IssueIDEnd><IssueArticleCount>21</IssueArticleCount><IssueHistory><CoverDate><Year>1987</Year><Month>6</Month></CoverDate></IssueHistory><IssueCopyright><CopyrightHolderName>Springer-Verlag</CopyrightHolderName><CopyrightYear>1987</CopyrightYear></IssueCopyright></IssueInfo><Article ID="Art2"><ArticleInfo Language="En" ArticleType="OriginalPaper" NumberingStyle="Unnumbered" TocLevels="0" ContainsESM="No"><ArticleID>BF00314280</ArticleID><ArticleDOI>10.1007/BF00314280</ArticleDOI><ArticleSequenceNumber>2</ArticleSequenceNumber><ArticleTitle Language="En">Adjuvant treatment of Parkinson's disease with budipine: a double-blind trial versus placebo</ArticleTitle><ArticleCategory>Original Investigations</ArticleCategory><ArticleFirstPage>280</ArticleFirstPage><ArticleLastPage>282</ArticleLastPage><ArticleHistory><RegistrationDate><Year>2004</Year><Month>8</Month><Day>25</Day></RegistrationDate><Received><Year>1986</Year><Month>7</Month><Day>14</Day></Received><Revised><Year>1986</Year><Month>9</Month><Day>1</Day></Revised><Accepted><Year>1986</Year><Month>9</Month><Day>8</Day></Accepted></ArticleHistory><ArticleCopyright><CopyrightHolderName>Springer-Verlag</CopyrightHolderName><CopyrightYear>1987</CopyrightYear></ArticleCopyright><ArticleGrants Type="Regular"><MetadataGrant Grant="OpenAccess"></MetadataGrant><AbstractGrant Grant="OpenAccess"></AbstractGrant><BodyPDFGrant Grant="Restricted"></BodyPDFGrant><BodyHTMLGrant Grant="Restricted"></BodyHTMLGrant><BibliographyGrant Grant="Restricted"></BibliographyGrant><ESMGrant Grant="Restricted"></ESMGrant></ArticleGrants><ArticleContext><JournalID>415</JournalID><VolumeIDStart>234</VolumeIDStart><VolumeIDEnd>234</VolumeIDEnd><IssueIDStart>5</IssueIDStart><IssueIDEnd>5</IssueIDEnd></ArticleContext></ArticleInfo><ArticleHeader><AuthorGroup><Author AffiliationIDS="Aff1" CorrespondingAffiliationID="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Kurt</GivenName><FamilyName>Jellinger</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff2"><AuthorName DisplayOrder="Western"><GivenName>Harald</GivenName><FamilyName>Bliesath</FamilyName></AuthorName></Author><Affiliation ID="Aff1"><OrgDivision>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology</OrgDivision><OrgName>Lainz Hospital</OrgName><OrgAddress><Street>Wolkersbergenstrasse 1</Street><Postcode>A-1130</Postcode><City>Vienna</City><Country>Austria</Country></OrgAddress></Affiliation><Affiliation ID="Aff2"><OrgName>Byk Gulden Research Center</OrgName><OrgAddress><Postcode>D-7750</Postcode><City>Konstanz</City><Country>Federal Republic of Germany</Country></OrgAddress></Affiliation></AuthorGroup><Abstract ID="Abs1" Language="En"><Heading>Summary</Heading><Para>Budipine, a new 4,4-diphenylpiperidine derivative, and placebo were administered three times daily to 31 patients with Parkinson's disease over a period of 12 weeks. All patients in the two treatment groups received levodopa (plus benserazide) at an optimum and constant dose for at least 2 months before the start of the study and throughout the trial. The additional administration of budipine (daily dose 60 mg) was excellently tolerated by 14 patients, while 2 patients left the study because of mental confusion at an early stage of the trial. The budipine group showed a 22% improvement on the Columbia Rating Scale (median score). Compared with the placebo group (4% improvement), there was a highly significant difference (<Emphasis Type="Italic">P</Emphasis><0.01, one-tailed test). Of the three main symptoms of Parkinson's disease, the best effect was seen on tremor, and less pronounced effects on bradykinesia and rigidity. Owing to its long half-life (31 h) with little plasma level fluctuations, budipine appears to be an effective agent in the treatment of Parkinson's disease.</Para></Abstract><KeywordGroup Language="En"><Heading>Key words</Heading><Keyword>Parkinson's disease</Keyword><Keyword>Budipine</Keyword><Keyword>Adjuvant treatment</Keyword><Keyword>Tremor</Keyword></KeywordGroup></ArticleHeader><NoBody></NoBody></Article></Issue></Volume></Journal></Publisher></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Adjuvant treatment of Parkinson's disease with budipine: a double-blind trial versus placebo</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Adjuvant treatment of Parkinson's disease with budipine: a double-blind trial versus placebo</title></titleInfo><name type="personal" displayLabel="corresp"><namePart type="given">Kurt</namePart><namePart type="family">Jellinger</namePart><affiliation>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology, Lainz Hospital, Wolkersbergenstrasse 1, A-1130, Vienna, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Harald</namePart><namePart type="family">Bliesath</namePart><affiliation>Byk Gulden Research Center, D-7750, Konstanz, Federal Republic of Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="OriginalPaper"></genre><originInfo><publisher>Springer-Verlag</publisher><place><placeTerm type="text">Berlin/Heidelberg</placeTerm></place><dateCreated encoding="w3cdtf">1986-07-14</dateCreated><dateIssued encoding="w3cdtf">1987-06-01</dateIssued><copyrightDate encoding="w3cdtf">1987</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">Summary: Budipine, a new 4,4-diphenylpiperidine derivative, and placebo were administered three times daily to 31 patients with Parkinson's disease over a period of 12 weeks. All patients in the two treatment groups received levodopa (plus benserazide) at an optimum and constant dose for at least 2 months before the start of the study and throughout the trial. The additional administration of budipine (daily dose 60 mg) was excellently tolerated by 14 patients, while 2 patients left the study because of mental confusion at an early stage of the trial. The budipine group showed a 22% improvement on the Columbia Rating Scale (median score). Compared with the placebo group (4% improvement), there was a highly significant difference (P<0.01, one-tailed test). Of the three main symptoms of Parkinson's disease, the best effect was seen on tremor, and less pronounced effects on bradykinesia and rigidity. Owing to its long half-life (31 h) with little plasma level fluctuations, budipine appears to be an effective agent in the treatment of Parkinson's disease.</abstract><note>Original Investigations</note><relatedItem type="host"><titleInfo><title>Journal of Neurology</title></titleInfo><titleInfo type="abbreviated"><title>J Neurol</title></titleInfo><genre type="Journal" displayLabel="Archive Journal"></genre><originInfo><dateIssued encoding="w3cdtf">1987-06-01</dateIssued><copyrightDate encoding="w3cdtf">1987</copyrightDate></originInfo><subject><genre>Medicine & Public Health</genre><topic>Neurosciences</topic><topic>Neuroradiology</topic><topic>Neurology</topic></subject><identifier type="ISSN">0340-5354</identifier><identifier type="eISSN">1432-1459</identifier><identifier type="JournalID">415</identifier><identifier type="IssueArticleCount">21</identifier><identifier type="VolumeIssueCount">6</identifier><part><date>1987</date><detail type="volume"><number>234</number><caption>vol.</caption></detail><detail type="issue"><number>5</number><caption>no.</caption></detail><extent unit="pages"><start>280</start><end>282</end></extent></part><recordInfo><recordOrigin>Springer-Verlag, 1987</recordOrigin></recordInfo></relatedItem><identifier type="istex">736AE8781BD70ADB7075C0C3EF16996111DBDE1B</identifier><identifier type="DOI">10.1007/BF00314280</identifier><identifier type="ArticleID">Art2</identifier><identifier type="ArticleID">BF00314280</identifier><accessCondition type="use and reproduction" contentType="copyright">Springer-Verlag</accessCondition><recordInfo><recordContentSource>SPRINGER</recordContentSource><recordOrigin>Springer-Verlag, 1987</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A45 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000A45 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:736AE8781BD70ADB7075C0C3EF16996111DBDE1B
|texte= Adjuvant treatment of Parkinson's disease with budipine: a double-blind trial versus placebo
}}
| This area was generated with Dilib version V0.6.23. |  |